title: Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
abstract: OBJECTIVE
  To examine the effect of sequential use of the antiprogesterone RU486 and synthetic progestin on ovarian function of healthy women.
  
  
  METHODS
  Healthy women were given a sequential antiprogesterone-progestin treatment. Blood samples were taken twice a week during one control cycle and one to three treatment cycles; prospective analysis.
  
  
  METHODS
  The outpatient clinic of the Helsinki City Maternity Hospital, Helsinki, Finland, and Steroid Research Laboratory, Department of Medical Chemistry, University of Helsinki, Helsinki, Finland.
  
  
  METHODS
  Eleven healthy women, volunteers, 20 to 34 years of age.
  
  
  METHODS
  A dose of 25 mg/d of RU486 was given during cycle days 1 to 21, and synthetic progestin (5 mg of norethisterone to six and 5 mg of medroxyprogesterone acetate to five women) during cycle days 22 to 31.
  
  
  METHODS
  Serum P, E2, FSH, and LH were measured from serum samples.
  
  
  RESULTS
  In 20 of the 24 treatment cycles analyzed the serum concentrations of P were anovulatory. In the remaining 4 cycles, P levels rose above 3 ng/mL, suggestive of ovulation. Folliculogenesis was not completely inhibited, but serum E2 profiles were subnormal and delayed. Bleeding control was satisfactory.
  
  
  CONCLUSIONS
  Antiprogesterone RU486 hampers or delays follicular development, suggesting a possible use as an estrogen-free oral contraceptive. However, the synthetic progestins used in this regimen induced serum P rises in some cycles. The synthetic progestin provides the cycle control, but its possible effect on the reliability of the method remains to be evaluated.
authors.affiliation: University of Helsinki, City Maternity Hospital, Finland.
authors.forename: R
authors.initials: R
authors.lastname: Kekkonen
authors.forename: P
authors.initials: P
authors.lastname: Lähteenmäki
authors.forename: T
authors.initials: T
authors.lastname: Luukkainen
authors.forename: J
authors.initials: J
authors.lastname: Tuominen
mesh_terms: D000328:Adult; D003276:Contraceptives, Oral; D004334:Drug Administration Schedule; D004958:Estradiol / Q000097:blood; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood; D006065:Gonadotropins, Pituitary / Q000097:blood; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology; D008598:Menstruation / Q000187:drug effects; D015735:Mifepristone / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D009640:Norethindrone / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D006080:Ovarian Follicle / Q000187:drug effects; D011374:Progesterone / Q000097:blood; D011446:Prospective Studies
chemical_list: D003276:Contraceptives, Oral; D012739:Gonadal Steroid Hormones; D006065:Gonadotropins, Pituitary; D015735:Mifepristone; D011374:Progesterone; D004958:Estradiol; D017258:Medroxyprogesterone Acetate; D009640:Norethindrone